Pancreatic Cancer Research

ResearcherNational Cancer CenterActive in the last 2 years

Sun‐Young Kong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-0620-4058; OpenAlex author ID A5090141367. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 3 papers · 2025: 3 papers · 2026: 1 paper

Papers 14

  1. Prognostic Value and Longitudinal Dynamics of Multigene Circulating Tumor DNA in Advanced Pancreatic Cancer Treated with 5-Fluorouracil-Based Chemotherapy. Last author DOI 10.3390/ijms27198668↗
  2. ATR inhibition promotes synergistic antitumor effect in platinum-resistant pancreatic cancer. Co-author DOI 10.1016/j.bbadis.2024.167625↗
  3. Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicente… Last author DOI 10.1093/clinchem/hvaf066↗
  4. Mutant KRAS and GATA6 Stratify Survival in Patients Treated with Chemotherapy for Pancreatic Adenocarcinoma: A Prospective Cohort Study. Co-author DOI 10.3390/cancers17050896↗
  5. PRMT1 promotes pancreatic cancer development and resistance to chemotherapy. Co-author DOI 10.1016/j.xcrm.2024.101461↗
  6. New Function Annotation of PROSER2 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1021/acs.jproteome.3c00632↗
  7. Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. Last author DOI 10.1111/cas.16104↗
  8. Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.4143/crt.2023.291↗
  9. Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohort Study. Last author DOI 10.3390/cancers13215466↗
  10. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Co-author DOI 10.1038/s41598-019-53271-6↗
  11. Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Sam… Co-author DOI 10.3389/fonc.2019.00875↗
  12. Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuva… Co-author DOI 10.5009/gnl18355↗
  13. Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1373/clinchem.2017.283721↗
  14. Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine fo… Co-author DOI 10.4143/crt.2016.495↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sang Myung Woo · 12 shared papers, 2017–2025 · strength 1.79
  2. Yun‐Hee Kim · 11 shared papers, 2017–2025 · strength 1.61
  3. Woo Jin Lee · 10 shared papers, 2017–2026 · strength 1.55
  4. Jung Won Chun · 6 shared papers, 2023–2026 · strength 1.29
  5. Sang‐Jae Park · 9 shared papers, 2017–2025 · strength 1.20
  6. Sung‐Sik Han · 8 shared papers, 2017–2025 · strength 0.99
  7. Min Kyeong Kim · 6 shared papers, 2017–2025 · strength 0.73
  8. Kyong‐Ah Yoon · 6 shared papers, 2017–2024 · strength 0.61
  9. Yu‐Sun Lee · 3 shared papers, 2019–2025 · strength 0.48
  10. Sang Hyub Lee · 2 shared papers, 2025 · strength 0.42
  11. Mi Rim Lee · 2 shared papers, 2024–2025 · strength 0.41
  12. Tae Hyun Kim · 3 shared papers, 2017–2025 · strength 0.37
  13. Jin‐Hyeok Hwang · 2 shared papers, 2021–2025 · strength 0.33
  14. Gi Yeon Lee · 1 shared paper, 2026 · strength 0.30
  15. Changhoon Yoo · 1 shared paper, 2026 · strength 0.30
  16. Sung Yong Choi · 2 shared papers, 2019–2024 · strength 0.27
  17. Eui Joo Kim · 1 shared paper, 2025 · strength 0.22
  18. Min Kyu Jung · 1 shared paper, 2025 · strength 0.22
  19. Dong‐Won Ahn · 1 shared paper, 2025 · strength 0.22
  20. Hyeong Min Park · 1 shared paper, 2025 · strength 0.22
  21. Hye Won Shon · 1 shared paper, 2025 · strength 0.20
  22. Woo Hyun Paik · 1 shared paper, 2025 · strength 0.20
  23. In Rae Cho · 1 shared paper, 2025 · strength 0.20
  24. Sung Jun Kim · 1 shared paper, 2025 · strength 0.20
  25. Ji Kon Ryu · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.